# NCT02115295 (NCT02115295)

> Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

No report yet. It can be ordered.

- Drugs tested: venetoclax plus CLIA; CLIA
- Indication: acute myeloid leukemia or high-risk myelodysplastic syndrome

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02115295
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Blasts 10 Percent or More of Peripheral Blood White Cells; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
- Interventions: Cladribine; Cytarabine; Gilteritinib; Idarubicin; Laboratory Biomarker Analysis; Midostaurin; Venetoclax
- Enrollment: 508
- Primary outcome: Complete response (CR) rate

## Indexed commentary on NCT02115295 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02115295